Regeneron; Pfizer hit with Covid-19 therapeutic suits
‘Gold standard’ reagent technology used totreat Covid-19 subject of suit against pharmagiants
A San-Diego based therapeutics firm is suing Regeneron,Pfizer and BioNTech over the alleged infringements of a reagent used
intherapeutics aimed at fighting Covid-19.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.